title: mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
abstract: The proof of principle that a drug targeting mTOR can improve survival has been obtained recently from a large randomised trial using temsirolimus as a first-line therapy in patients with advanced poor prognostic renal cell carcinoma. Consistent data have recently shown the important role of the PI3K/AKT/mTOR signalling pathway in the regulation of crucial metabolic and mitotic functions of cancer cells and endothelial cells allowing a better understanding of the role of mTOR in controlling cancer cell proliferation and survival as well as tumour angiogenesis. As a result, rapamycin derivatives (rapalogues) that block mTOR/Raptor complex 1 were shown to exert direct antiproliferative effects against endometrial cancers, in which cancer cells frequently lose PTEN function as well as mantle cell lymphomas, in which cancer cell proliferation appears to be driven primarily by cyclin D1 overexpression. The overall antitumour effects of rapalogues in renal cell carcinoma appear to be more complex with tumour growth inhibition resulting from direct G1/S cell cycle blockage and/or apoptotic effects in carcinoma cells along with the inhibition of downstream signalling of the HIF1alpha-induced VEGF/VEGFR autocrine loop in endothelial cells shutting down the maintenance of tumour angiogenesis. Despite extensive cognitive researches, it is difficult to appraise which of those mechanisms is predominant in patients. This review focuses on mechanisms of action of rapalogues focusing on antitumour effects in patients with renal cell carcinoma.
authors.affiliation: Department of Medical Oncology, APHP and INSERM U728, RayLab, Beaujon University Hospital, Clichy, France.
authors.forename: C
authors.initials: C
authors.lastname: Le Tourneau
authors.forename: S
authors.initials: S
authors.lastname: Faivre
authors.forename: M
authors.initials: M
authors.lastname: Serova
authors.forename: E
authors.initials: E
authors.lastname: Raymond
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D000076222:Mechanistic Target of Rapamycin Complex 1; D046912:Multiprotein Complexes; D011506:Proteins; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases; D014157:Transcription Factors / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D046912:Multiprotein Complexes; D011506:Proteins; D014157:Transcription Factors; C401859:temsirolimus; D000076222:Mechanistic Target of Rapamycin Complex 1; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31
references.pmid: 17671154
references.citation: Nat Rev Drug Discov. 2007 Sep;6(9):734-45
references.pmid: 17690708
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5347-56
references.pmid: 15983389
references.citation: J Clin Pharmacol. 2007 Nov;47(11):1430-9
references.pmid: 17913896
references.citation: Genes Dev. 2005 Sep 1;19(17):2054-65
references.pmid: 16107612
references.citation: Ann Oncol. 2005 Jun;16(6):928-33
references.pmid: 15851405
references.citation: J Clin Oncol. 2004 Jun 15;22(12):2336-47
references.pmid: 15136596
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Nat Rev Drug Discov. 2006 Aug;5(8):671-88
references.pmid: 16883305
references.citation: Br J Cancer. 2008 Mar 11;98(5):923-30
references.pmid: 18319715
references.citation: Mod Pathol. 2002 May;15(5):479-85
references.pmid: 12011252
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1596-602
references.pmid: 18332467
references.citation: J Biol Chem. 2002 Apr 26;277(17):15162-70
references.pmid: 11859074
references.citation: Int J Cancer. 2002 May 1;99(1):53-7
references.pmid: 11948491
references.citation: J Urol. 2005 May;173(5):1496-501
references.pmid: 15821467
references.citation: Am J Obstet Gynecol. 2007 Mar;196(3):247.e1-5
references.pmid: 17346540
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1603-10
references.pmid: 18332469
references.citation: Cancer Res. 1999 Aug 1;59(15):3581-7
references.pmid: 10446965
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3958-64
references.pmid: 17761980
references.citation: Nat Med. 2002 Feb;8(2):128-35
references.pmid: 11821896
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5755-63
references.pmid: 17020981
references.citation: Apoptosis. 2004 Nov;9(6):797-805
references.pmid: 15505422
references.citation: Clin Cancer Res. 2001 Apr;7(4):892-5
references.pmid: 11309338
references.citation: J Clin Oncol. 2008 Jan 20;26(3):361-7
references.pmid: 18202410
references.citation: Chest. 2008 Feb;133(2):528-38
references.pmid: 18252919
references.citation: Oncol Rep. 2005 Aug;14(2):389-92
references.pmid: 16012720
references.citation: Nat Med. 2006 Jan;12(1):122-7
references.pmid: 16341243
references.citation: Ther Clin Risk Manag. 2007 Jun;3(2):341-8
references.pmid: 18360643
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: J Clin Oncol. 2004 Mar 1;22(5):909-18
references.pmid: 14990647
references.citation: Clin Cancer Res. 2007 Dec 15;13(24):7401-6
references.pmid: 18094423
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1588-95
references.pmid: 18332470
references.citation: J Clin Oncol. 2006 Jan 1;24(1):25-35
references.pmid: 16314617